R-021 ( DrugBank: - )

1 disease

ID	Disease name (Link within this page)	Number of trials
222	Primary nephrotic syndrome	1

222. Primary nephrotic syndrome

Clinical trials : 285 / Drugs : 285 - (DrugBank : 108) / Drug target genes : 62 - Drug target pathways : 191

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2016-005141-23-IT (EUCTR)	17/09/2018	15/01/2021	Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis ( ...	A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan ...	Focal segmental glomerulosclerosis (FSGS) MedDRA version: 21.1;Level: PT;Classification code 1006775 ...	Product Name: Sparsentan Product Code: [R-021] Trade Name: Irbesartan Product Name: IRBESARTAN Product C ...	RETROPHIN, INC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	300	Phase 3	United States;Portugal;Taiwan;Hong Kong;Estonia;Spain;Italy;Switzerland;France;Australia;Denmark;Sou ...

First Previous1Next Last